Thiard News@F4F

@newsen.bsky.social

1 week ago

Jazz Pharmaceuticals to Showcase Innovations in Neurology at AAN Annual Meeting At the upcoming 2026 AAN Annual Meeting, Jazz Pharmaceuticals will present significant research on Epidiolex and Xywav, targeting rare neurological disorders.

Jazz Pharmaceuticals to Showcase Innovations in Neurology at AAN Annual Meeting #United_States #Chicago #Jazz_Pharmaceuticals #Epidiolex #Xywav

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Jazz Pharmaceuticals Set to Make a Mark at 25th Annual Needham Healthcare Conference Jazz Pharmaceuticals will participate in the Needham Healthcare Conference, featuring key discussions on their innovative biopharmaceutical developments.

Jazz Pharmaceuticals Set to Make a Mark at 25th Annual Needham Healthcare Conference #Ireland #Dublin #Biopharma #Jazz_Pharmaceuticals #Needham_Conference

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Innovative Partnership Between American Nutrition Association and Jazz Pharmaceuticals to Combat Sodium-Related Health Risks The American Nutrition Association collaborates with Jazz Pharmaceuticals to promote sodium reduction awareness for better cardiovascular health, targeting narcolepsy and IH patients.

Innovative Partnership Between American Nutrition Association and Jazz Pharmaceuticals to Combat Sodium-Related Health Risks #United_States #Chicago #Jazz_Pharmaceuticals #American_Nutrition_Association #Sodium_Reduction

Thiard News@F4F

@newsen.bsky.social

1 month ago

Jazz Pharmaceuticals Unveils Groundbreaking Clinical Advances in Oncology at AACR 2026 Jazz Pharmaceuticals is set to present key clinical findings at AACR 2026, including advancements in HER2-targeted treatments and promising preclinical data on new oncology compounds.

Jazz Pharmaceuticals Unveils Groundbreaking Clinical Advances in Oncology at AACR 2026 #Ireland #Dublin #Jazz_Pharmaceuticals #oncology_research #AACR_2026

Thiard News@F4F

@newsen.bsky.social

1 month ago

Jazz Pharmaceuticals Reports Strong Financial Performance for 2025 and Projects Growth for 2026 Jazz Pharmaceuticals has announced a remarkable financial performance in 2025, with $4.3 billion in total revenue. The company anticipates continued growth in 2026 supported by robust new product launches.

Jazz Pharmaceuticals Reports Strong Financial Performance for 2025 and Projects Growth for 2026 #USA #Dublin #Jazz_Pharmaceuticals #Epidiolex #Xywav

Thiard News@F4F

@newsen.bsky.social

1 month ago

Jazz Pharmaceuticals Reveals Stellar Financial Performance and 2026 Guidance Jazz Pharmaceuticals announces impressive 2025 financial results, showing significant revenue growth and projects a strong forecast for 2026, led by key product launches.

Jazz Pharmaceuticals Reveals Stellar Financial Performance and 2026 Guidance #Jazz_Pharmaceuticals #HER2-targeted_therapy #Pipeline_Products

Thiard News@F4F

@newsen.bsky.social

3 months ago

Jazz Pharmaceuticals Welcomes Thomas Riga as New Chief Business Officer in 2026 Thomas Riga has been appointed Chief Business Officer at Jazz Pharmaceuticals. He brings over 25 years of experience in corporate operations and development.

Jazz Pharmaceuticals Welcomes Thomas Riga as New Chief Business Officer in 2026 #Ireland #Dublin #Jazz_Pharmaceuticals #Modeyso #Thomas_Riga

Thiard News@F4F

@newsen.bsky.social

3 months ago

Ziihera® Achieves Groundbreaking Success in Treating HER2+ Metastatic GEA, Offering Hope for Patients with Improved Survival Rates Ziihera® has redefined treatment in HER2+ metastatic gastroesophageal adenocarcinoma, showcasing significant survival benefits and setting a new standard in patient care.

Ziihera® Achieves Groundbreaking Success in Treating HER2+ Metastatic GEA, Offering Hope for Patients with Improved Survival Rates #Ireland #Dublin #Jazz_Pharmaceuticals #Ziihera® #HER2+_GEA

Thiard News@F4F

@newsen.bsky.social

4 months ago

Jazz Pharmaceuticals Engages in Significant Investor Events for 2026 Jazz Pharmaceuticals has announced its participation in key investor events in early 2026, showcasing its latest advancements and strategies in healthcare.

Jazz Pharmaceuticals Engages in Significant Investor Events for 2026 #Ireland #Dublin #investor_events #Jazz_Pharmaceuticals #Zanidatamab

Thiard News@F4F

@newsen.bsky.social

4 months ago

Jazz Pharmaceuticals Sets the Stage for 2026 with Key Investor Events and Insights Jazz Pharmaceuticals is gearing up for significant investor events in January 2026, showcasing pivotal oncology research and corporate strategy.

Jazz Pharmaceuticals Sets the Stage for 2026 with Key Investor Events and Insights #Ireland #Dublin #investor_events #Jazz_Pharmaceuticals #Zanidatamab

Thiard News@F4F

@newsen.bsky.social

4 months ago

Jazz Pharmaceuticals Unveils New Research at 2025 American Epilepsy Society Meeting Jazz Pharmaceuticals showcased new data on Epidiolex® at the AES 2025 Annual Meeting, emphasizing its impact on treatment-resistant epilepsies.

Jazz Pharmaceuticals Unveils New Research at 2025 American Epilepsy Society Meeting #United_States #Atlanta #Jazz_Pharmaceuticals #Epidiolex #AES_2025

Thiard News@F4F

@newsen.bsky.social

4 months ago

Jazz Pharmaceuticals to Share Groundbreaking Ziihera Phase 3 Results at 2026 ASCO GI Symposium Jazz Pharmaceuticals is set to present important Phase 3 results for Ziihera® in two abstracts at the upcoming ASCO GI Symposium, highlighting advancements in treating HER2-positive gastroesophageal cancers.

Jazz Pharmaceuticals to Share Groundbreaking Ziihera Phase 3 Results at 2026 ASCO GI Symposium #United_States #San_Francisco #ZIIHERA #Jazz_Pharmaceuticals #HER2-positive

Thiard News@F4F

@newsen.bsky.social

5 months ago

Jazz Pharmaceuticals to Engage at Citi's 2025 Global Healthcare Conference in December Jazz Pharmaceuticals is set to participate in Citi's 2025 Global Healthcare Conference, showcasing its commitment to innovative biopharma.

Jazz Pharmaceuticals to Engage at Citi's 2025 Global Healthcare Conference in December #Ireland #Dublin #biotechnology #Jazz_Pharmaceuticals #Global_Healthcare_Conference

Thiard News@F4F

@newsen.bsky.social

5 months ago

Positive HERIZON-GEA-01 Phase 3 Findings Support Ziihera as First-Line Treatment for HER2-Positive Cancer The Phase 3 HERIZON-GEA-01 trial shows Ziihera plus chemotherapy improves patient outcomes significantly for HER2-positive gastroesophageal adenocarcinoma.

Positive HERIZON-GEA-01 Phase 3 Findings Support Ziihera as First-Line Treatment for HER2-Positive Cancer #ZIIHERA #Ireland #Dublin #Jazz_Pharmaceuticals #HER2

Thiard News@F4F

@newsen.bsky.social

5 months ago

Jazz Pharmaceuticals Unveils Groundbreaking Data on Modeyso for Rare Brain Tumor Treatment at SNO 2025 Jazz Pharmaceuticals presents significant new research on Modeyso™, aimed at treating H3 K27M mutant diffuse midline glioma, at SNO 2025.

Jazz Pharmaceuticals Unveils Groundbreaking Data on Modeyso for Rare Brain Tumor Treatment at SNO 2025 #United_States #Honolulu #Jazz_Pharmaceuticals #Modeyso #H3_K27M

Thiard News@F4F

@newsen.bsky.social

5 months ago

Jazz Pharmaceuticals Reports Strong Third Quarter 2025 Results and Inspirational Updates on Financial Guidance Jazz Pharmaceuticals has announced robust financial results for the third quarter of 2025, showcasing a 7% revenue increase and significant product launches.

Jazz Pharmaceuticals Reports Strong Third Quarter 2025 Results and Inspirational Updates on Financial Guidance #USA #Dublin #Jazz_Pharmaceuticals #Epidiolex #Modeyso

Thiard News@F4F

@newsen.bsky.social

5 months ago

Jazz Pharmaceuticals Reports Impressive Q3 2025 Financial Results and Updates 2025 Outlook Jazz Pharmaceuticals has revealed its third-quarter financial results for 2025, showcasing substantial revenue growth and strategic updates for the future.

Jazz Pharmaceuticals Reports Impressive Q3 2025 Financial Results and Updates 2025 Outlook #USA #Dublin #Jazz_Pharmaceuticals #Epidiolex #Modeyso

Thiard News@F4F

@newsen.bsky.social

5 months ago

Jazz Pharmaceuticals Welcomes Dr. Ted W. Love to its Board, Aiming for Growth and Innovation Jazz Pharmaceuticals has appointed Dr. Ted W. Love to its Board of Directors, effective December 1, 2025, to enhance growth and innovation strategies.

Jazz Pharmaceuticals Welcomes Dr. Ted W. Love to its Board, Aiming for Growth and Innovation #Ireland #Dublin #Board_of_Directors #Jazz_Pharmaceuticals #Dr._Ted_Love

Thiard News@F4F

@newsen.bsky.social

6 months ago

Transformative Findings on Xywav® Treatment Presented at Global Sleep and Psychiatry Events Jazz Pharmaceuticals recently unveiled pivotal Phase 4 data and real-world evidence for Xywav® treatment in narcolepsy during major international conferences.

Transformative Findings on Xywav® Treatment Presented at Global Sleep and Psychiatry Events #None #Jazz_Pharmaceuticals #Narcolepsy #Xywav

Thiard News@F4F

@newsen.bsky.social

7 months ago

Modeyso™: A Revolutionary Treatment for H3 K27M-mutant Diffuse Glioma Launched Jazz Pharmaceuticals introduces Modeyso™, the first authorized therapy for H3 K27M-mutant diffuse gliomas. This breakthrough treatment is now included in NCCN guidelines.

Modeyso™: A Revolutionary Treatment for H3 K27M-mutant Diffuse Glioma Launched #United_States #Dublin #Jazz_Pharmaceuticals #H3_K27M #Modeyso™

Thiard News@F4F

@newsen.bsky.social

7 months ago

Jazz Pharmaceuticals to Engage at the 2025 Wells Fargo Healthcare Conference Jazz Pharmaceuticals is set to participate in the upcoming 2025 Wells Fargo Healthcare Conference with a key management fireside chat.

Jazz Pharmaceuticals to Engage at the 2025 Wells Fargo Healthcare Conference #healthcare #Ireland #Dublin #Jazz_Pharmaceuticals #Wells_Fargo

Thiard News@F4F

@newsen.bsky.social

7 months ago

Jazz Pharmaceuticals and Saniona Collaborate on Innovative Epilepsy Treatment with New Licensing Agreement Jazz Pharmaceuticals has secured exclusive rights to SAN2355, a next-gen epilepsy treatment. This collaboration promises groundbreaking advancements in neurological therapy.

Jazz Pharmaceuticals and Saniona Collaborate on Innovative Epilepsy Treatment with New Licensing Agreement #Ireland #Dublin #Jazz_Pharmaceuticals #SAN2355 #Saniona

Thiard News@F4F

@newsen.bsky.social

8 months ago

FDA Approves Modeyso™ as First Treatment for Recurrent H3 K27M-Mutant Glioma Jazz Pharmaceuticals has received FDA approval for Modeyso™, the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma, a rare brain tumor primarily affecting children.

FDA Approves Modeyso™ as First Treatment for Recurrent H3 K27M-Mutant Glioma #United_States #Dublin #Jazz_Pharmaceuticals #Modeyso #H3_K27M

Thiard News@F4F

@newsen.bsky.social

8 months ago

Jazz Pharmaceuticals Reports Strong Q2 2025 Results and Leadership Change Jazz Pharmaceuticals announced its Q2 2025 financial results, showcasing significant revenue growth and updating its financial guidance. A new CEO will take the helm, driving future growth.

Jazz Pharmaceuticals Reports Strong Q2 2025 Results and Leadership Change #USA #Dublin #Jazz_Pharmaceuticals #Xywav #Zepzelca

Thiard News@F4F

@newsen.bsky.social

8 months ago

Jazz Pharmaceuticals Reports Second Quarter 2025 Performance and CEO Transition Jazz Pharmaceuticals announces its financial results for Q2 2025, showcasing revenue growth and key updates on its pipeline and leadership transition.

Jazz Pharmaceuticals Reports Second Quarter 2025 Performance and CEO Transition #USA #Dublin #Jazz_Pharmaceuticals #Xywav #Zepzelca

Thiard News@F4F

@newsen.bsky.social

9 months ago

Renee Gala Takes Charge as New CEO of Jazz Pharmaceuticals in Strategic Transition Renee Gala has been named the new President and CEO of Jazz Pharmaceuticals, succeeding Bruce Cozadd. Her extensive experience positions her for success in this pivotal role.

Renee Gala Takes Charge as New CEO of Jazz Pharmaceuticals in Strategic Transition #Ireland #Dublin #Jazz_Pharmaceuticals #Bruce_Cozadd #Renee_Gala

Thiard News@F4F

@newsen.bsky.social

9 months ago

Jazz Pharmaceuticals Gains EU Approval for Ziihera® to Treat Advanced Biliary Tract Cancer Jazz Pharmaceuticals has received conditional EU marketing authorization for Ziihera® (zanidatamab), targeting advanced HER2-positive biliary tract cancer, providing hope for patients with limited treatment options.

Jazz Pharmaceuticals Gains EU Approval for Ziihera® to Treat Advanced Biliary Tract Cancer #ZIIHERA #Ireland #Dublin #Jazz_Pharmaceuticals #biliary_tract_cancer

Thiard News@F4F

@newsen.bsky.social

10 months ago

FDA Grants Priority Review for Innovative Lung Cancer Therapy Combining Zepzelca and Atezolizumab Jazz Pharmaceuticals received FDA acceptance for Zepzelca® paired with Atezolizumab as a treatment for extensive-stage lung cancer, marking a significant development for patient care.

FDA Grants Priority Review for Innovative Lung Cancer Therapy Combining Zepzelca and Atezolizumab #United_States #Dublin #Jazz_Pharmaceuticals #Zepzelca #Atezolizumab

Thiard News@F4F

@newsen.bsky.social

10 months ago

Jazz Pharmaceuticals Unveils New Data on Xywav Treatment for Narcolepsy at SLEEP 2025 Conference At SLEEP 2025, Jazz Pharmaceuticals presented significant Phase 4 findings on their low-sodium oxybate Xywav for narcolepsy treatment, showcasing promising outcomes.

Jazz Pharmaceuticals Unveils New Data on Xywav Treatment for Narcolepsy at SLEEP 2025 Conference #Ireland #Dublin #Jazz_Pharmaceuticals #Narcolepsy #Xywav

Thiard News@F4F

@newsen.bsky.social

10 months ago

Jazz Pharmaceuticals Announces Encouraging Survival Data for Ziihera® in Cancer Treatment at ASCO 2025 Jazz Pharmaceuticals shared promising long-term survival data for Ziihera®, showing a median overall survival of 36.5 months in patients treated for HER2-positive metastatic gastroesophageal adenocarcinoma at ASCO 2025.

Jazz Pharmaceuticals Announces Encouraging Survival Data for Ziihera® in Cancer Treatment at ASCO 2025 #ZIIHERA #Ireland #Dublin #Jazz_Pharmaceuticals #Zanidatamab